Julia Gaebler | Former Senior Director of Global Medical Outcomes Strategy
Biogen Idec

Dr. Gaebler was Senior Director, Global Medical Outcomes Strategy at Biogen Idec, Inc., where she provided strategic leadership and technical expertise to ensure that global medical product strategies and tactics integrate the evolving demands of the global payer landscape. As Director, Global Market Access at Biogen, Dr. Gaebler developed and managed a team of health economists who conducted payer value research for launch and late-stage MS products. In this capacity, she managed the EU market access launch of TECFIDERA. Prior Biogen, Dr. Gaebler was Director, HEOR at Amylin Pharmaceuticals in San Diego, where she supported the company's diabetes and obesity assets. In addition to her positions in industry, Dr. Gaebler was Health Policy Researcher at RAND, where she applied decision analytic methods to policy issues in public health prevention and infectious disease policy. Using a range of modeling methods, her research has explored the effectiveness and cost-effectiveness of medical and diagnostic interventions for HIV, hepatitis B and C, sexually transmitted diseases, pandemic influenza, and diabetes and hypertension. She has also conducted pharmacoeconomic and Quality of Life/PRO analyses and early phase modeling supporting HIV, hepatitis and oncology compounds in Phase II/III clinical trials. Dr. Gaebler received her PhD in Health Policy from Harvard University, an MA in International Affairs and Economics from Johns Hopkins University, and a BA from the University of Pennsylvania. She has held Adjunct positions at UCSD Division of Global Public Health and at the RAND Corporation.